TG6050

TG6050 an innovative oncolytic virus from the Invir.IO® platform.

TG6050 has been engineered to express into the tumor, human IL-12, a cytokine that triggers a powerful antitumor immune response, and a full length anti-CTLA4 antibody.

Specifically multiply and induce tumor cell lysis (or oncolysis).

 

Derived from the Invir.IO® platform, our oncolytic viruses infect, specifically multiply and induce tumor cell lysis (or oncolysis).

These viruses also integrate anti-cancer weapons into their genome, enabling them to modulate the tumor microenvironment.

These different mechanisms lead to the destruction of tumor cells and the activation of the immune system, while preserving the patient’s own healthy cells.

Designed to induce a strong immune response against the tumor

 

Additional ressources

 

Last press releases